EVERSANA built a generative AI regulatory review tool on Amazon Bedrock and Textract.
Regulatory review of branded materials takes thousands of hours and is error-prone. EVERSANA used Bedrock and Textract to annotate documents, find claims, score risk and flag compliance issues with human reviewers in the loop. The page gives no figures and describes reviewers becoming more attuned to where the models go wrong.
EVERSANA is a pharma commercialization services company, used by life sciences firms for medical, legal and regulatory content review and AI-assisted commercial work
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by EVERSANA on its own site — read the original case study on drugdiscoverytrends.com ↗
Note: Trade-press interview; no quantified results.
Related use cases
- 01OpenAI's dedicated healthcare vertical page/launch post.
- 02Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 03follow-up update to the life-sciences model.
- 04"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.
- 05Moderna and OpenAI partner to accelerate development of treatments; ChatGPT Enterprise deployed to thousands of employees company-wide.
- 06Longevity biotech collaborated with OpenAI to build and research GPT-4b micro, a version of GPT-4o specialized for protein engineering.